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Abstract 
Background: Literature has demonstrated proper antibiotic selection and prompt initiation of antibiotics are associated with lower 
morbidity and mortality. Septic patients have altered pharmacokinetics and often require continuous renal replacement therapy 
which contributes to altered drug clearance and metabolism. The current study evaluates the pharmacokinetics of meropenem and 
piperacillin/tazobactam in critically-ill patients requiring continuous veno-venous hemodiafiltration. 
Purpose: This observational, prospective, single-center, nonrandomized study evaluated the pharmacokinetics of meropenem and 
piperacillin/tazobactam in critically-ill patients requiring continuous veno-venous hemodiafiltration.  
Methods: Plasma drug concentrations were determined via high-performance liquid chromatography using three post-dose blood 
samples after steady-state antimicrobial agent administration. 
Results: Meropenem peak drug concentrations ranged from 35.9 to 61 mcg/mL, while trough concentrations ranged from 3.9 to 16.7 
mcg/mL. Piperacillin peak drug concentrations ranged from 240 to 331.8 mcg/mL, while trough concentrations ranged from 152.7 to 
194.9 mcg/mL. Both drugs examined displayed peak concentrations relatively consistent with those expected from the literature, but 
observed trough concentrations for meropenem and piperacillin were uniformly high. 
Conclusions: Intravenous doses of meropenem and piperacillin result in peak drug concentrations similar to those previously reported 
and trough concentrations significantly greater than those in the literature. While concentrations above an organism’s MIC are 
desirable given the time-dependent nature of these beta-lactam antibiotics, decreased renal clearance of patients maintained on 
CVVHDF therapy while receiving higher doses of antimicrobials creates a situation in which drug accumulation and toxicity may 
occur. Given the complex nature of ICU patient care, increased pharmacovigilance and therapeutic drug monitoring are necessary in 
this unique population. 
 
 
Introduction 
Admissions to intensive care units (ICU) for sepsis have 
increased dramatically over the past 15 yearsi. Hall and 
colleagues demonstrated that a greater proportion of 
septicemia or sepsis hospitalizations end in death when 
compared with other hospitalized populations (17% versus 
2%, respectively). Furthermore, a greater proportion of 
hospitalizations include sepsis or septicemia as a principal or 
secondary diagnosis. This figure increased from over 620,000 
in 2000 to over 1.1 million in 2008. During this period, the 
overall number of hospitalizations did not change, but the  
rate of these hospitalizations increased by 70% between  
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2000 and 2008. Those who survive sepsis or septicemia may 
have permanent organ dysfunction or other irreversible 
manifestations.  
 
Gaieske et al demonstrated that proper antibiotic selection 
and prompt initiation of antibiotics are associated with lower 
mortalityii. An analysis of patients with septic shock 
demonstrated that time to initiation of antimicrobial therapy 
was the strongest predictor of mortality. It was also 
demonstrated that inappropriate antibiotic selection was 
common, occurring in 32% of septic patients2. Mortality was 
nearly doubled in this group compared to those patients with 
appropriately selected antibiotics (34% versus 18%). 
Pathogen recovery is often limited, therefore, a broad-
spectrum antimicrobial agent is often chosen for empiric 
treatment. Two such agents are meropenem and 
piperacillin/tazobactamiii. 
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Renal injury requiring renal replacement therapy – including 
intermittent hemodialysis as well as various types of 
continuous renal replacement therapy – is estimated to occur 
in as many as 5% of ICU patients4. There is limited data 
supporting adequate dosing of medications for patients 
receiving renal replacement therapy. Estimating drug removal 
is complicated due to many factors including extracorporeal 
drug removal in addition to pharmacokinetic changes due to 
the underlying diseaseiv,v. Furthermore, these changes are 
not applicable to all patients receiving continuous renal 
replacement (CRRT) due to differences in techniques and 
instrumentation across institutions.  
 
To estimate drug removal during CRRT many factors must be 
considered, including the pharmacokinetics and 
pharmacodynamics of the medication, interaction between 
the extracorporeal membrane and the medication, method of 
solute transport used for CRRT which may be by diffusion or 
convection and finally clinical significance of the medication 
clearance dependent on the extracorporeal circuit4,5,vi,vii. 
Many medications exhibit a multi-compartment distribution 
that is not affected largely by intermittent dialysis as the rate 
of removal exceeds the redistribution rate. CRRT affects the 
volume of distribution at a much slower rate, thus allowing 
for continuous redistribution to plasma and increasing the 
available drug for removal4.  
 
CRRT has several variants for the nephrologist to customize in 
order to provide individualized care. Continuous veno-venous 
hemofiltration (CVVH) which relies on convection for solute 
transport and thus is able to remove large particles (< 20kDa), 
continuous veno-venous hemodialysis (CVVHD) utilizes 
diffusive solute transport and thus limits extraction to smaller 
particles (< 300 Da), continuous veno-venous 
hemodiafiltration (CVVHDF) however incorporates both 
diffusion and convection to remove particles and thus has the 
capability to remove a broader range of particle sizes5,7,viii, ix.  
 
The current study is an institutional review board approved 
observational, prospective, single-center, nonrandomized 
study evaluating the pharmacokinetics of meropenem and 
piperacillin/tazobactam in critically ill patients requiring 
CVVHDF that took place from May 2013 to January 2014. The 
studied antimicrobials were selected due to their clinical 
significance. Meropenem and piperacillin/tazobactam are the 
two most commonly used broad spectrum, antimicrobial 
agents with activity against Pseudomonas sp. at our 
institution. Additionally, there is an absence of an established 
standard for routine therapeutic drug monitoring with these 
agents. 
 
The primary objective of this study is to describe the 
clearance of meropenem and piperacillin/tazobactam to 
better understand the pharmacokinetics of two commonly 
used antibiotics used in the treatment of critically-ill patients 
simultaneously receiving CVVHDF therapy.  A secondary 
objective was to evaluate the observed pharmacokinetics 
compared with previously published data for patients not 
requiring CVVHDF.  
 
Methods 
Study Design and Patient Population 
Our institution has an adult critical care unit comprised of a 
14-bed medical ICU, a 21-bed surgical ICU and a 16-bed 
cardiovascular ICU with medical ICU overflow. Patients 
included in this study were treated by the medical ICU team 
with either meropenem or piperacillin/tazobactam while 
simultaneously receiving CVVHDF for a minimum of 24 hours. 
Patients were excluded if they were under 18 years of age, 
over 75 years of age, prescribed custom dialysate solutions, 
experienced frequent CVVHDF interruptions1,  or had residual 
renal function (defined as urine output >400 mL in the 24 
hour period preceding the post-dose lab draw window).  
Women who were pregnant or less than three months post-
partum and patients with anticipated life expectancy of less 
than 24 hours were also excluded from the study. Eligible 
patients or their medical decision makers were approached 
by the primary investigator(s) to explain the study and obtain 
consent prior to study-specific lab draws taking place. 
 
Antimicrobial Dosing and Serum Sample Collection 
All patients within our institution receiving CVVHDF 
treatment and concomitant antimicrobial therapy with either 
meropenem or piperacillin/tazobactam, regardless of study 
eligibility, receive protocol-driven, renally-adjusted 
antimicrobial dosing (meropenem 1 gram intravenously every 
eight hours infused over 30 minutes or 
piperacillin/tazobactam 4.5 grams intravenously every six 
hours infused over 60 minutes). Both of these doses are 
greater than standard doses (500mg IV every six hours for 
meropenem, 3.375g IV every six hours for 
piperacillin/tazobactam) within our institution to account for 
increased clearance due to CVVHDF therapy. 
 
                                                 
1 Frequent CVVHDF interruption was defined as two or more 
interruptions lasting less than four hours each within a 24 
hour period. Prolonged CVVHDF interruption was defined as a 
cessation of CVVHDF for greater than four hours during the 
post dose lab window. Patients were re-considered for 
eligibility after a 24 hour period with no additional 
interruptions, 
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After at least 24 hours of continuous meropenem or 
piperacillin/tazobactam therapy with concurrent CVVHDF, 
three blood samples were collected by trained unit nursing 
staff via a pre-existing central venous catheter. Samples were 
drawn 0-30 minutes post-infusion (peak), 2.5-3 hours post-
infusion (midpoint), and 0- 30 minutes prior to end of the 
dosing interval (trough). The time between infusion initiation 
through the end of the dosing interval was defined as the lab 
draw window. If CVVHDF encountered interruptions during 
the lab draw window, nursing staff were instructed to contact 
study personnel to determine if sampling could be continued. 
Blood samples were collected in 4 mL lavender-top tubes 
containing ethylenediaminetetraacetic acid (EDTA). Samples 
were placed on ice and delivered to the acute care laboratory 
immediately after collection.  
 
Whole blood samples were processed to separate and isolate 
plasma following established laboratory protocol within two 
hours of collection. Isolated plasma was stored at -80 degrees 
Celsius until enrollment and sample collection was complete. 
 
Dialysis Procedure and Drug Concentration Analysis 
CRRT was performed using a PrismaFlex (Gambro) machine 
with M100 hemofilter and institution-standard solutions 
(PrismaSol BGK, Gambro, Lakewood, CO). CVVHDF was run 
via large bore vein access and settings were recorded for 
each patient during the lab draw period. 
Meropenem and piperacillin concentrations were determined 
via high-performance liquid chromatography (HPLC) using 
cefuroxime as an internal standard. 
 
Results 
Five piperacillin/tazobactam and four meropenem subjects 
consented to the study and had at least one blood sample 
collected. Of these subjects, one in the meropenem group 
was excluded due nursing collection error, and two in the 
piperacillin/tazobactam group were excluded due to sample 
contamination (Figure 1). The three subjects that remained in 
each group are reported below as a case series. Relevant 
clinical, demographic, and treatment information for all 
patients was obtained from the electronic health record and 
is reported in Table 1.  
 
Meropenem (Figure 2) 
Case 1 
A 52 year old male status post myeloablative allogeneic bone 
marrow transplant who was admitted for acute respiratory 
failure concerning for infection versus worsening graft-
versus-host disease. Meropenem was initiated on admission, 
and CVVHDF was started on day one of admission. The 
evening prior to the lab draw window, the patient 
encountered a brief interruption in CVVHDF to allow for 
circuit change. The estimated down time was one hour. The 
patient’s urine output during this time was decreasing, with 
an estimated output of 291 mL in the preceding 24 hours. 
Labs were significant for hypoalbuminemia. Sample collection 
occurred on day three of meropenem and the resulting 
concentrations were 61 mcg/mL, 39.4 mcg/mL and 16.7 
mcg/mL for the peak, midpoint and trough concentrations, 
respectively. The calculated volume of distribution (Vd) for 
this patient was 17.1 L and estimated drug half-life was 3.6 
hours.  
 
Case 2 
A 47 year old female who was admitted for pneumonia with 
worsening chest infiltrates. Meropenem initiated on day four 
of admission, and CVVHDF was started on day 12 of 
admission. During the lab draw window the patient 
encountered no interruptions in CVVHDF. Urine output 
during this time was increasing, with an estimated output of 
262 mL in the preceding 24 hours. Labs were significant for 
hypoalbuminemia and a mild elevation in alkaline 
phosphatase. Sample collection occurred on day 17 of 
meropenem and the resulting concentrations were 47.3 
mcg/mL, 13.6 mcg/mL and 3.9 mcg/mL for the peak, midpoint 
and trough concentrations, respectively. Calculated Vd for 
this patient was 15.4 L and estimated drug half-life was 1.9 
hours.  
 
Case 3 
A 33 year old male with a history of alcoholic cirrhosis, 
hepatitis and pancreatitis who was admitted for cholecystitis 
and Enterococcus faecalis sepsis. The patient received several 
courses of meropenem during prolonged hospital stay with 
restart two days prior to lab draw for healthcare associated 
pneumonia, CVVHDF was started six days prior to the lab 
draw window. Approximately 24 hours prior to the lab draw 
window the patient encountered a brief interruption in 
CVVHDF for a circuit change due to clotting. The estimated 
down time was one hour. The patient produced no urine 
output during the 24 hours prior to lab sampling. Labs were 
significant for severe hepatic impairment with 
hypoalbuminemia, moderately elevated alkaline phosphatase 
and AST, and significantly elevated total bilirubin. Sample 
collection occurred after the fifth dose of meropenem and 
the resulting concentrations were 35.9 mcg/mL, 20.5 mcg/mL 
and 14.1 mcg/mL for the peak, midpoint and trough 
concentrations, respectively. Calculated Vd for this patient 
was 34.4 L and estimated drug half-life was 4.6 hours.  
 
Piperacillin/tazobactam (Figure 3) 
Case 1 
A 55 year old male with no remarkable past medical history 
was admitted for acute liver decompensation, acute kidney 
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injury and microscopic polyangiitis with diffuse alveolar 
hemorrhage. Piperacillin/tazobactam was initiated on the 
third day of admission, which was one day after CVVHDF 
initiation. No CVVHDF interruptions occurred within 24 hours 
prior to or during the lab draw window. The patient produced 
37 mL of urine during the 24 hours prior to lab sampling. Labs 
were significant for hypoalbuminemia and significantly 
elevated total bilirubin, AST, and ALT. Sample collection 
occurred on the eighth day of admission, after 24 hours of 
concurrent piperacillin/tazobactam and CVVHDF therapy. The 
resulting piperacillin concentrations were 311.9 mcg/mL, 
243.3 mcg/mL and 194.9 mcg/mL for the peak, midpoint and 
trough concentrations, respectively. Calculated Vd for this 
patient was 22.2 L and calculated piperacillin half-life was 5.8 
hours.  
 
Case 2 
A 49 year old female with a history of scleroderma, 
pulmonary hypertension, pulmonary fibrosis, breast cancer 
status post mastectomy and reconstruction, chronic hepatitis 
C, and hypothyroidism who was admitted for acute hypoxic 
respiratory failure and septic shock requiring vasopressor 
support. Piperacillin/tazobactam and CVVHDF were initiated 
one day after admission, which was six days prior to the lab 
draw window. Approximately 1.5 hours prior to the lab draw 
window the patient encountered a brief interruption in 
CVVHDF for increased pressures. No urine output occurred 
during the 24 hours prior to lab sampling. Labs were 
significant for hypoalbuminemia and moderately elevated 
alkaline phosphatase and total bilirubin. Sample collection 
occurred on the seventh day of admission and the resulting 
piperacillin concentrations were 239.9 mcg/mL, 183.5 
mcg/mL and 152.7 mcg/mL for the peak, midpoint and trough 
concentrations, respectively. Calculated Vd for this patient 
was 30.9 L and estimated half-life was 6.3 hours.  
 
Case 3 
A 35 year old male with a history of mechanical aortic and 
mitral valve replacements and severe pulmonic stenosis who 
was admitted for sepsis from an infected thrombus in an 
atriovenous fistula. Piperacillin/tazobactam was initiated on 
day six of admission, one day prior to CVVHDF. Approximately 
14 hours prior to the lab draw window there was a brief 
machine malfunction resulting in CRRT interruption. Patient 
had no urine output during the 24 hours prior to lab 
sampling. Labs were significant for hypoalbuminemia, 
moderately elevated total bilirubin, and significantly elevated 
AST and ALT. Sample collection occurred on the eighth day of 
admission, after 24 hours of concurrent 
piperacillin/tazobactam and CVVHDF therapy. The resulting 
piperacillin concentrations were 331.8 mcg/mL, 276.1 
mcg/mL and 182.5 mcg/mL for the peak, midpoint and trough 
concentrations, respectively. Calculated Vd for this patient 
was 18.5 L and calculated piperacillin half-life was 5.0 hours. 
 
Discussion 
This observational, prospective, single-center, 
nonrandomized study evaluating the pharmacokinetics of 
meropenem and piperacillin-tazobactam in critically ill 
patients requiring CVVHDF provided insight about the plasma 
concentrations of two antimicrobial agents commonly used in 
critically ill patients requiring CVVHDF at our institution. 
 
Previous studies have reported pharmacokinetics of 
meropenem and piperacillin in renal replacement therapy 
patients, but variations in study design and methods have 
prevented clear conclusions from being drawn about drug 
elimination in this subset of patients6. 
 
Antimicrobial treatment of critically ill patients in the ICU is 
complex due to factors such as resistant organisms, 
immunosuppression, and concomitant medical diagnoses and 
interventions. The time-dependent, bactericidal nature of 
beta-lactam antibiotics necessitates antimicrobial 
concentrations above the minimum inhibitory concentration 
(MIC) for 40-50% of the dosing interval for optimal 
bactericidal activityx. The two antimicrobial agents studied 
are frequently used to treat potential Pseudomonas 
aeruginosa infections. Pseudomonas aeruginosa is a common 
pathogen that has demonstrated increasing resistance and is 
frequently isolated from critically ill patients at our 
institution. For this reason, comparison of observed drug 
concentrations to MIC breakpoints for this organism will be 
made. 
 
Meropenem peak drug concentrations ranged from 35.9 to 
61 mcg/mL, while trough concentrations ranged from 3.9 to 
16.7 mcg/mL. Compared to reported values for healthy 
volunteersxi, the observed concentrations tended to be 
higher, especially at the end of the dosing interval. 
Meropenem peak concentrations were not well correlated 
with literature values, while trough concentrations were 
uniformly higher than expected values, revealing a potentially 
decreased rate of elimination.  
 
Using a Pseudomonas aeruginosa MIC breakpoint of 4 
mcg/mLxii, only one concentration was observed below the 
MIC, indicating that meropenem concentrations above the 
MIC were achieved for an adequate period throughout the 
lab draw window in all three patients. From an antimicrobial 
efficacy perspective, these drug concentrations would be 
expected to contribute to optimal antibacterial efficacy 
against pathogens susceptible to this agent. 
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While no specific reports of adverse events relating to 
meropenem were recorded in these patients, the risk for 
drug accumulation and subsequent toxicity increases with 
increasing drug concentrations. Trough concentrations 
observed in this study were several-fold higher than those 
observed in healthy volunteers, which could prompt the need 
for increased pharmacovigilance and adverse event 
monitoring. Common side effects of meropenem injection 
include headache, nausea, diarrhea, pain, and anemia11. 
 
Piperacillin peak drug concentrations ranged from 240 to 
331.8 mcg/mL, while trough concentrations ranged from 
152.7 to 194.9 mcg/mL. Compared to reported values for 
healthy volunteersxiii , piperacillin peak concentrations are 
somewhat similar to the literature, but midpoint and trough 
concentrations are significantly higher than literature values. 
The pharmacokinetic profiles including therapeutic peaks and 
elevated troughs observed for all three patients are similar, 
suggesting a decreased rate of elimination for patients on 
CVVHDF therapy. 
 
No concentrations were observed below the Pseudomonas 
aeruginosa MIC breakpoint of 32 mcg/mL11. In fact, the 
lowest observed concentration was about five times greater 
than this breakpoint. As observed in the meropenem group, 
these high drug concentrations would be expected to 
contribute to optimal antibacterial efficacy against pathogens 
susceptible to this agent. 
 
Similar to the meropenem group, no reports of adverse 
events relating to piperacillin/tazobactam administration or 
accumulation were recorded in these patients, although 
greatly elevated trough concentrations observed in this study 
should prompt the need for increased pharmacovigilance and 
adverse event monitoring. Common side effects of 
piperacillin/tazobactam injection include headache, nausea, 
diarrhea, constipation, insomnia, and pruritis13. 
 
Drug Concentration Implications 
While both drugs examined displayed peak concentrations 
consistent with those expected from the literature, observed 
trough concentrations for meropenem and piperacillin were 
uniformly high. While concentrations above an organism’s 
MIC are desirable given the time dependent nature of these 
beta-lactam antibiotics, the decreased renal clearance of 
patients maintained on CVVHDF therapy while receiving 
higher doses of antimicrobials creates a situation in which 
drug accumulation and potential toxicity may occur.  
 
While patients enrolled in this study had CRRT interruptions 
monitored closely and were excluded if interruptions were 
frequent or prolonged, CRRT is often interrupted for planned 
or unplanned reasons. During this time, antimicrobial 
medication doses may still be given, despite CRRT clearance 
being temporarily absent. This may lead to drug 
concentrations even higher than those observed in this study 
and a presumably higher risk of adverse events due to 
prolonged elevation in drug concentrations. 
 
Potential mechanisms by which elevated troughs and 
associated toxicity may be avoided include dose reduction 
and dosing interval extension. As peak concentrations were 
relatively consistent with therapeutic literature values, dosing 
interval extension is likely the most effective method by 
which lower troughs could be attained while maintaining 
therapeutic peaks. For example, increasing the interval of 
piperacillin/tazobactam from six hours to eight hours or 12 
hours would still achieve the peak concentrations desired for 
therapeutic efficacy, but would also give patients a longer 
period to clear the drug, thereby reducing their plasma drug 
concentrations and decreasing the risk of associated toxicity. 
Further study in this area is warranted to fully assess the 
potential for toxicity of these agents and investigate 
mechanisms and dosing strategies to avoid these adverse 
events. 
 
Strengths 
The present study examined the pharmacokinetics of two 
commonly used antimicrobial medications in critically ill 
patients requiring CVVHDF therapy. Patients in this study 
were treated for multiple indications and had varied 
demographic and clinical parameters. Samples were collected 
after steady-state would have been expected to occur, and 
interruptions in CVVHDF therapy were controlled for. 
 
Additionally, the study was observational in nature and 
provided results based on actual clinical care without 
changing existing practices. As a result, interruptions in 
CVVHDF, slight variations in dose administration, 
performance of diagnostic tests and other aspects of routine 
patient care are incorporated into our results and reflect 
actual clinical practice when compared to well-controlled 
studies. 
 
Limitations 
The small number of patients enrolled from a single-center 
decrease the widespread applicability of the presented 
information. A majority of the patients treated with CVVHDF 
at our institution suffer from concomitant hepatic 
impairment, which may not represent the patient 
characteristics of other centers, further limiting the 
applicability of results. 
 
 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                      2015, Vol. 6, No. 2, Article 204                         INNOVATIONS in pharmacy   6 
 
Conclusions 
Critically ill patients requiring CVVHDF have altered 
pharmacokinetics of antimicrobial agents. Intravenous doses 
of meropenem 1 gram every eight hours and 
piperacillin/tazobactam 4 grams/0.5 grams every six hours 
result in peak drug concentrations similar to those previously 
reported and trough concentrations significantly greater than 
those in the literature. Given the complex nature of ICU 
patient care, increased pharmacovigilance and therapeutic 
drug monitoring are warranted in this unique population. 
Further study of pharmacokinetics in CVVHDF patients is 
necessary to achieve greater understanding of drug 
elimination and metabolism in the setting of continuous renal 
replacement. 
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Table 1: Patient Clinical and Demographic Information 
 
  
   Meropenem Piperacillin 
  Patient 1 Patient 2 Patient 3 Patient 1 Patient 2 Patient 3 
Gender Male Female Male Male Female Male 
Age 52 48 33 55 49 35 
Weight (kg) 154.2 67.2 113 68.2 78.8 69.3 
Height (m) 1.8 1.57 1.85 1.67 1.6 1.6 
BSA (m2) 2.78 1.71 2.41 1.78 1.87 1.75 
Antimicrobial 
Indication HCAP HCAP Sepsis 
UTI, Possible 
sepsis Septic shock Sepsis 
Antimicrobial 
(mg/kg) per Dose 6.5 14.9 8.8 14.7 12.7 14.4 
AST/ALT 34/66 102/49 128/40 172/111 37/55 2133/114 
Total bilirubin 0.4 0.5 23.2 23.1 4.4 4.7 
Albumin 2.3 1.9 2.6 2 2.1 2.7 
Urine Output (mL) 
(Preceding 24 hr) 291 262 0 37 0 0 
Vd (L) 17.1 15.4 34.4 22.2 30.9 18.5 
t1/2 (hours) 3.6 1.9 4.6 5.8 6.3 5 
Circuit Type CVVHDF CVVHDF CVVHDF CVVHDF CVVHDF CVVHDF 
Filter M100 M100 M100 M100 M100 M100 
Blood Flow Rate 
(mL/min) 200 140 200 180 200 180 
Ultrafiltrate rate 
(mL/hr) 1800 900 1700 1000 1200 700 
Dialysate rate 
(mL/hr) 1800 800 1700 1000 1000 1000 
Patient Survival No No No No Yes No 
 
All data obtained from electronic medical record. Values reported were most recent available prior to lab 
draw window. 
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Figure 1: Patient enrollment and inclusion summary for 
meropenem and piperacillin/tazobactam groups 
 
 
 
 
 
 
Figure 2: Meropenem plasma concentrations over time in study subjects during lab draw window 
(compared with literature values extrapolated from healthy volunteers given 1 gram meropenem dose) 
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Figure 3: Piperacillin plasma concentrations over time in study subjects during lab draw window  
(compared with literature values reported for healthy volunteers given 4 gram piperacillin dose) 
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